...
首页> 外文期刊>癌と化学療法 >A case of recurrent gastric cancer tolerant to TS-1 therapy successfully treated by TS-1 combined with docetaxel
【24h】

A case of recurrent gastric cancer tolerant to TS-1 therapy successfully treated by TS-1 combined with docetaxel

机译:TS-1联合多西他赛成功治疗复发耐受TS-1的胃癌1例

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

We report a case of a 58-year-old man with advanced gastric cancer producing sialyl-Tn antigen (STN). Total gastrectomy with distal pancreatectomy and splenectomy was performed. Pathological staging was IV (T 3 N 2 CY1), and most of the cancer cells were strongly positive for anti-STN antibody on immunohistochemical stainings. Serum STN level before the operation was 2,500 U/ml, and the value significantly decreased to the normal range (< 45 U/ml) 2 months after the operation. Low-dose FP (5-FU+CDDP) followed by TS-1 alone (80 mg/day) had been performed as adjuvant chemotherapy. Jaundice appeared and the serum STN level increased again 22 months after the operation. He was diagnosed with a recurrence in the hilar lymph node of the liver. After implantation of expandable stent in the common bile duct, triweekly docetaxel therapy with TS-1 administration (day 1-14) has been performed. Three courses of this therapy have induced a complete response of the recurrent lymph node and the normalization of the serum STN value. No major adverse reaction to this therapy was observed. A complete response and good patient QOL have been achieved during follow-up 8 months after the administration of TS-1 with docetaxel. This case suggests that patients with recurrent gastric cancer who have undergone prior therapy with TS-1 alone could benefit from TS-1 with docetaxel therapy as a second line.
机译:我们报告了一例58岁的晚期胃癌患者,产生唾液酸-Tn抗原(STN)。进行了全胃切除术,远端胰腺切除术和脾切除术。病理分期为IV(T 3 N 2 CY1),并且大多数癌细胞在免疫组织化学染色中均强烈显示抗STN抗体阳性。术前血清STN水平为2500 U / ml,术后2个月血清STN水平明显下降至正常范围(<45 U / ml)。小剂量FP(5-FU + CDDP)继之以TS-1(80 mg / day)作为辅助化疗。术后22个月出现黄疸,血清STN水平再次升高。他被诊断出肝门淋巴结复发。将可扩张支架植入胆总管后,已进行了三周的多西他赛联合TS-1给药疗法(第1-14天)。此疗法的三个疗程已引起复发性淋巴结完全反应和血清STN值正常化。没有观察到对该疗法的主要不良反应。在将TS-1与多西他赛一起给药后8个月的随访中,已经获得了完整的反应和良好的患者QOL。该病例表明,仅接受TS-1先前治疗的复发性胃癌患者可以从多西他赛治疗的TS-1中获益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号